ClinicalTrials.gg

How we know

Every link on this study, and who decided it

The study on the left, the conditions and drugs this site links it to, and on each link the judgments that made or checked it, by day and by judge. The top row is the record itself: each new version seen since tracking began. Dashed lines are links the registry record does not make itself. Select a link to see everything judged on it, or a mark for one decision with its reason and evidence.

5 links0 made here, not in the record5 judgments2 judges (the rules as one: Rule based)3 record changes seen
Claude Opus 5.5Rule basedRecord updated on ClinicalTrials.gov
Oct 5Oct 12Oct 19Oct 26Nov 2Nov 9Nov 16TodayNCT05092958Testing the Addition of theAnti-cancer Drug,Cabozantinib, to the UsualImmunotherapy Treatment,Avelumab, in Patients WithMetastatic UrothelialCancer, MAIN-CAV StudyNational Cancer Institute (NCIPhase 3 · active not recruitinRECORDThe record itselfVersions seen nightly since Sep 25, 2…›Oct 1 · ClinicalTrials.gov record · Version of 2026-10-01Oct 26 · ClinicalTrials.gov record · Version of 2026-10-26Nov 12 · ClinicalTrials.gov record · Version of 2026-11-12Version of 2026-11-12CONDITIONSUrinary Bladder NeoplasmsThe registry's MeSH filing›As of now · Rule based · Main conditionMain conditionUreteral NeoplasmsThe registry's MeSH filing›No judgment recorded. Shown as the registry files it.Urethral NeoplasmsThe registry's MeSH filing›No judgment recorded. Shown as the registry files it.DRUGSAvelumabIntervention entry›Nov 3 · Claude Opus 5.5 · BackgroundNov 18 · Rule based · BackgroundBackgroundCabozantinibEntry “Cabozantinib S-malate”, read b…›Nov 3 · Claude Opus 5.5 · TestedNov 18 · Rule based · BackgroundTested

Times are in your time zone; a day marked “day only” kept no time. The graph scrolls sideways on a narrow screen; every mark is also in the list below.

Avelumab

From the registry record2 judgments on this link
Role in the study, from the registry to what was judged
RegistryEntry “Avelumab”the record gives no role
→judged=agrees
How the 2 judgments split100%of judgments with a known value say Background
Background · 2

All judgments on this study

WhenLinkJudgeDecisionState
Oct 1The record itselfClinicalTrials.gov recordVersion of 2026-10-01Record change
Oct 26The record itselfClinicalTrials.gov recordVersion of 2026-10-26Record change
Nov 3AvelumabClaude Opus 5.5BackgroundCurrent
Nov 3CabozantinibClaude Opus 5.5TestedCurrent
Nov 12The record itselfClinicalTrials.gov recordVersion of 2026-11-12Record change
Nov 18AvelumabRule based · role ruleBackgroundAgrees
Nov 18CabozantinibRule based · role ruleBackgroundOverridden
As of nowUrinary Bladder NeoplasmsRule based · main-condition ruleMain conditionCurrent

The rules, in plain words

“Rule based” means one of these decided, not a model or a person. Each runs every night over every study.

Which drugs a study tests

Reads each treatment the study lists and the arms it is in. A drug only in the experimental arm is tested. A drug in every arm while something else changes between the arms is given beside it. A drug only in the control arm is the comparator. Placebo, procedures and usual care are known by name.

Where the whole record has been read, that reading's answer replaces the rule's.

What a study is mainly about

Starts from the first condition ClinicalTrials.gov files the study under. It moves to a narrower one only when the study's own title or listed conditions name it, and sets aside terms the registry often files by mistake. A study open to many cancers is not placed under one of them unless its title names it.

Checked against studies judged one by one; the study page says when it differs from the registry.